客服微v信：
手机APP
移动版
第四批国采即将于下月执行，前三批国采目前执行进展如何，是许多小伙伴都很关心的问题。 近日，江西省公布了前三批国采在最新采购周期的采购情况，数据截止至 2021 年 2 月 28 日，来看一下，你的品种超额完成采购指标了吗？ 详情分享如下： 第一批国采（4+7扩围） 国家组织药品集中采购和使用试点扩围（即4+7扩围）中选结
-
采购数量和金额：25个中选药品的31个品规在全省12个联盟地区采购总数量为13337.95万片/支/袋。按药品统计，最高为厄贝沙坦75mg的2345.89万片，最低为培美曲塞500mg的530瓶。全省采购总金额为12362.56万元，占同品规药品采购金额的70.29%。
-
中选药完成进度和占比：31个品规的全省采购总数量占第二个采购周期约定采购总量的比例为50.40%，占同品规所有药品采购总数量的比例为91.54%。
-
网上配送率：全省总体网上配送率为83.00%。
| 药品 | 采购金额 | 完成进度 | 中选药占比 |
| 阿托伐他汀口服常释剂型10mg | 998786.88 | 50.43% | 96.76% |
| 阿托伐他汀口服常释剂型20mg | 3077803.3 | 56.14% | 80.37% |
| 瑞舒伐他汀口服常释剂型10mg | 2167165.08 | 51.81% | 97.90% |
| 瑞舒伐他汀口服常释剂型5mg | 394627.35 | 56.22% | 82.33% |
| 氯吡格雷口服常释剂型75mg | 30821950.38 | 52.78% | 99.36% |
| 厄贝沙坦口服常释剂型75mg | 4549079.16 | 52.05% | 99.86% |
| 氨氯地平口服常释剂型5mg | 1136316.72 | 37.65% | 79.80% |
| 恩替卡韦口服常释剂型0.5mg | 2949760.96 | 46.94% | 91.79% |
| 艾司西酞普兰口服常释剂型10mg | 3989364.04 | 55.64% | 90.18% |
| 帕罗西汀口服常释剂型20mg | 1258292.03 | 56.26% | 98.36% |
| 奥氮平口服常释剂型10mg | 7179699.2 | 44.36% | 91.66% |
| 奥氮平口服常释剂型5mg | 5809661.7 | 48.63% | 96.85% |
| 头孢呋辛酯(头孢呋辛)口服常释剂型250mg | 1135829.52 | 60.16% | 97.23% |
| 利培酮口服常释剂型1mg | 622166.4 | 40.58% | 89.83% |
| 吉非替尼口服常释剂型250mg | 3368426 | 60.76% | 93.89% |
| 福辛普利口服常释剂型10mg | 217525.04 | 96.59% | 99.79% |
| 厄贝沙坦氢氯噻嗪口服常释剂型150mg+12.5mg | 4173487.08 | 54.94% | 97.68% |
| 赖诺普利口服常释剂型10mg | 22271.85 | 61.27% | 100.00% |
| 替诺福韦二吡呋酯口服常释剂型300mg | 357802.53 | 56.69% | 77.30% |
| 氯沙坦口服常释剂型100mg | 288996.7 | 62.00% | 99.36% |
| 氯沙坦口服常释剂型50mg | 5376067.24 | 73.51% | 98.42% |
| 依那普利口服常释剂型10mg | 1780016.9 | 67.07% | 99.06% |
| 依那普利口服常释剂型5mg | 736905.75 | 70.43% | 96.74% |
| 左乙拉西坦口服常释剂型250mg | 2293259.76 | 84.33% | 95.42% |
| 伊马替尼口服常释剂型100mg | 1396198.22 | 93.77% | 88.82% |
| 孟鲁司特口服常释剂型10mg | 3208901.64 | 69.30% | 99.55% |
| 蒙脱石口服散剂3g | 515004.95 | 60.70% | 95.25% |
| 培美曲塞注射剂100mg | 2474598 | 52.25% | 85.33% |
| 培美曲塞注射剂500mg | 1449989.9 | 38.52% | 99.62% |
| 氟比洛芬酯注射剂50mg/5ml | 3420578.25 | 58.59% | 95.28% |
| 右美托咪定注射剂0.2mg/2ml | 26455030 | 66.21% | 99.81% |
| 总计 | 123625562.5 | 50.40% | 91.54% |
-
采购数量和金额：32个中选药品的36个品规在全省12个联盟地区采购总数量为37506.86万片/支/袋。按药品统计，最高为阿卡波糖50mg的15402.17万片，最低为安立生坦5mg的2.37万片。全省采购总金额为14467.66万元，占同品规药品采购金额的64.50%。
-
中选药完成进度和占比：36个品规的全省采购总数量占约定采购总量的比例为297.53%，占同品规所有药品采购总数量的比例为87.76%。
-
网上配送率：全省总体网上配送率为76.71%。
| 药品 | 采购金额 | 完成进度 | 中选药占比 |
| 阿比特龙口服常释剂型0.25g | 14623584 | 5236.92% | 96.21% |
| 阿德福韦酯口服常释剂型10mg | 2569914 | 517.76% | 89.95% |
| 阿卡波糖口服常释剂型50mg | 27825450.1 | 342.30% | 88.28% |
| 阿卡波糖口服常释剂型100mg | 1206417.9 | 190.60% | 88.85% |
| 阿莫西林口服常释剂型0.25g | 3423396.06 | 416.47% | 81.75% |
| 阿莫西林口服常释剂型0.5g | 459037.68 | 59.37% | 67.59% |
| 阿奇霉素口服常释剂型0.25g | 2572410.12 | 99.46% | 79.22% |
| 安立生坦片剂5mg | 474000 | 1128.57% | 76.58% |
| 奥美沙坦酯口服常释剂型20mg | 579661.04 | 230.14% | 86.58% |
| 比索洛尔口服常释剂型2.5mg | 128498.5 | 98.04% | 87.23% |
| 比索洛尔口服常释剂型5mg | 3294676.1 | 268.81% | 83.20% |
| 对乙酰氨基酚口服常释剂型0.5g | 72362.55 | 171.30% | 95.15% |
| 多奈哌齐口服常释剂型5mg | 1321877.08 | 283.19% | 85.39% |
| 氟康唑口服常释剂型50mg | 497787.81 | 163.70% | 88.51% |
| 福多司坦口服常释剂型0.2g | 4208189.5 | 189.31% | 93.81% |
| 格列美脲口服常释剂型2mg | 2738444.48 | 325.05% | 93.17% |
| 甲硝唑口服常释剂型0.2g | 870498.72 | 283.49% | 92.94% |
| 聚乙二醇口服散剂10g | 646906.84 | 231.97% | 98.15% |
| 坎地沙坦酯口服常释剂型4mg | 3147882 | 151.68% | 82.38% |
| 克林霉素口服常释剂型0.15g | 51285.6 | 90.51% | 80.09% |
| 铝碳酸镁咀嚼片0.5g | 1387376.64 | 353.10% | 94.00% |
| 美洛昔康口服常释剂型7.5mg | 484502.88 | 274.36% | 94.17% |
| 莫西沙星口服常释剂型0.4g | 1415928.27 | 304.54% | 87.89% |
| 曲美他嗪缓释控释剂型35mg | 3122720.64 | 467.13% | 92.61% |
| 索利那新口服常释剂型5mg | 228074.48 | 199.94% | 76.62% |
| 他达拉非片剂20mg | 2564520.96 | 592.72% | 92.51% |
| 特拉唑嗪口服常释剂型2mg | 1984449.48 | 285.58% | 87.62% |
| 替吉奥口服常释剂型20mg | 9685728.8 | 130.09% | 86.85% |
| 替吉奥口服常释剂型25mg | 5640987.96 | 147.80% | 85.55% |
| 头孢氨苄口服常释剂型0.25g | 307438.04 | 211.65% | 89.81% |
| 头孢拉定口服常释剂型0.25g | 836173.44 | 310.86% | 75.28% |
| 辛伐他汀口服常释剂型20mg | 2619984.8 | 358.08% | 93.72% |
| 异烟肼口服常释剂型0.1g | 439678.56 | 353.63% | 87.94% |
| 吲达帕胺口服常释剂型2.5mg | 310898.52 | 271.87% | 95.53% |
| 紫杉醇（白蛋白结合型）粉针剂100mg | 42418740 | 667.69% | 85.73% |
| 左西替利嗪口服常释剂型5mg | 517082.55 | 243.34% | 88.53% |
| 总计 | 144676566.1 | 297.53% | 87.76% |
-
采购数量和金额：55个中选药品的66个品规在全省12个联盟地区采购总数量为14285.79万片/支/袋。按药品统计，最高为二甲双胍0.5g的1803.13万片，最低为依托考昔120mg的325片。全省采购总金额为6815.92万元，占同品规药品采购金额的51.64%。
-
中选药完成进度和占比：66个品规的全省采购总数量占约定采购总量的比例为56.94%，占同品规下所有药品采购总数量的比例为77.76%。
-
网上配送率：全省总体网上配送率为63.30%。
| 药 品 | 采购金额 | 完成进度 | 中选药占比 |
| 阿莫西林颗粒剂0.125g | 551605.34 | 145.02% | 92.52% |
| 阿那曲唑口服常释剂型1mg | 735821.27 | 109.28% | 92.06% |
| 阿哌沙班口服常释剂型2.5mg | 35923.68 | 135.67% | 100.00% |
| 阿扎胞苷注射剂100mg | 1104086 | 631.88% | 89.41% |
| 氨基葡萄糖口服常释剂型0.25g | 1665756.9 | 38.29% | 94.68% |
| 氨溴索口服常释剂型30mg | 568244.25 | 99.82% | 90.48% |
| 奥氮平口腔崩解片5mg | 203590.8 | 1290.21% | 99.69% |
| 奥氮平口腔崩解片10mg | 33351.75 | 236.64% | 98.86% |
| 奥美拉唑口服常释剂型20mg | 805963.19 | 50.26% | 86.16% |
| 布洛芬缓释控释剂型0.3g | 425827.2 | 45.43% | 67.36% |
| 布洛芬颗粒剂0.2g | 43999.95 | 110.40% | 95.77% |
| 地氯雷他定口服常释剂型5mg | 403166.72 | 236.08% | 96.89% |
| 多潘立酮口服常释剂型10mg | 866732.85 | 61.94% | 82.03% |
| 二甲双胍缓释控释剂型0.5g | 744359.1 | 67.44% | 57.44% |
| 二甲双胍口服常释剂型0.5g | 1177044.5 | 22.75% | 53.92% |
| 非布司他口服常释剂型40mg | 9541695.79 | 200.60% | 97.32% |
| 非那雄胺口服常释剂型1mg | 98670 | 529.84% | 95.09% |
| 非那雄胺口服常释剂型5mg | 721793.6 | 68.17% | 86.14% |
| 氟西汀口服常释剂型20mg | 433547.4 | 103.49% | 52.45% |
| 枸橼酸西地那非片剂25mg | 30725.4 | 3087.87% | 100.00% |
| 枸橼酸西地那非片剂50mg | 26699.82 | 525.12% | 100.00% |
| 枸橼酸西地那非片剂100mg | 41075.37 | 272.65% | 97.45% |
| 环丙沙星口服常释剂型0.25g | 43520.88 | 76.69% | 94.08% |
| 甲钴胺口服常释剂型0.5mg | 2723503.09 | 100.97% | 87.15% |
| 卡培他滨口服常释剂型0.15g | 91602.66 | 88.28% | 79.58% |
| 卡培他滨口服常释剂型0.5g | 3675133.2 | 94.85% | 80.23% |
| 卡托普利口服常释剂型25mg | 75111.9 | 56.92% | 87.38% |
| 克拉霉素口服常释剂型250mg | 408158.1 | 99.97% | 94.96% |
| 喹硫平口服常释剂型25mg | 17622 | 137.45% | 65.28% |
| 喹硫平口服常释剂型0.1g | 1914698.76 | 87.26% | 77.03% |
| 喹硫平口服常释剂型0.2g | 1464710.84 | 53.64% | 57.33% |
| 来曲唑口服常释剂型2.5mg | 3366152.48 | 154.97% | 89.51% |
| 利奈唑胺口服常释剂型600mg | 992211 | 645.91% | 94.18% |
| 氯氮平口服常释剂型25mg | 156862.4 | 50.88% | 67.71% |
| 美金刚口服常释剂型10mg | 377645 | 112.92% | 82.43% |
| 孟鲁司特咀嚼片4mg | 115927.92 | 95.12% | 95.75% |
| 孟鲁司特咀嚼片5mg | 275151.06 | 61.49% | 95.96% |
| 孟鲁司特颗粒剂0.5g:4mg | 554865.36 | 702.40% | 99.21% |
| 莫西沙星氯化钠注射剂250ml:莫西沙星0.4g与氯化钠2.0g | 5020499.2 | 133.72% | 83.48% |
| 匹伐他汀口服常释剂型1mg | 142541.6 | 15.98% | 71.40% |
| 匹伐他汀口服常释剂型2mg | 2986645.8 | 92.76% | 95.75% |
| 普芦卡必利口服常释剂型1mg | 1750.7 | 289.16% | 100.00% |
| 普芦卡必利口服常释剂型2mg | 37842.8 | 245.69% | 96.22% |
| 曲美他嗪口服常释剂型20mg | 290829.25 | 54.85% | 96.40% |
| 塞来昔布口服常释剂型0.2g | 380349.62 | 44.38% | 62.05% |
| 舍曲林口服常释剂型50mg | 1951137.44 | 86.85% | 67.42% |
| 坦洛新（坦索罗辛）缓释控释剂型0.2mg | 1474424.4 | 137.77% | 92.88% |
| 碳酸氢钠口服常释剂型0.5g | 847445.28 | 63.35% | 91.92% |
| 替格瑞洛口服常释剂型90mg | 6890247 | 106.93% | 85.00% |
| 头孢地尼口服常释剂型100mg | 1012203.04 | 27.11% | 92.86% |
| 头孢克洛口服常释剂型0.25g | 584316.69 | 87.15% | 96.62% |
| 托法替布口服常释剂型5mg | 833325 | 2845.78% | 90.47% |
| 维格列汀口服常释剂型50mg | 400571.62 | 61.27% | 94.19% |
| 维生素B6口服常释剂型10mg | 380466.45 | 69.48% | 83.96% |
| 西酞普兰口服常释剂型20mg | 550484.88 | 73.53% | 61.98% |
| 西替利嗪口服常释剂型10mg | 50821.7 | 50.02% | 88.46% |
| 缬沙坦口服常释剂型80mg | 1662129.37 | 101.38% | 87.83% |
| 盐酸达泊西汀片剂30mg | 164744.1 | 137.59% | 77.80% |
| 依托考昔口服常释剂型30mg | 785.4 | 12.55% | 100.00% |
| 依托考昔口服常释剂型60mg | 582639.6 | 134.64% | 90.18% |
| 依托考昔口服常释剂型120mg | 1405.3 | 270.83% | 100.00% |
| 乙胺丁醇口服常释剂型0.25g | 568986.68 | 71.67% | 84.68% |
| 右佐匹克隆口服常释剂型3mg | 809501.94 | 133.59% | 99.48% |
| 左氧氟沙星滴眼剂5ml:24.4mg | 1433361.05 | 85.07% | 87.59% |
| 左乙拉西坦口服液体剂10%（150ml:15g） | 62586 | 48.70% | 97.17% |
| 左乙拉西坦注射用浓溶液5ml:500mg | 2524555 | 1049.12% | 97.71% |
| 总计 | 68159154.44 | 56.94% | 77.76% |
本文来源：医药代表 作者：MRCLUB 免责声明：该文章版权归原作者所有，仅代表作者观点，转载目的在于传递更多信息，并不代表“医药行”认同其观点和对其真实性负责。如涉及作品内容、版权和其他问题，请在30日内与我们联系
点赞 0 反对 0 举报 0
收藏 0
分享 2
吉利德挖走安进研发高管
« 上一篇 2021-04-01 11:27
医保局设定时限：3月底前，全国药品要完成价格调整
下一篇 » 2024-01-04 19:54
1570
0
京公网安备 11010802031568号
